68 research outputs found
Π ΠΎΠ»Ρ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π‘677Π’ Π³Π΅Π½Π° MTHFR Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΠΠ‘ ΠΈ Π³ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π΄ΠΈΡΠ»ΠΈΠΏΠΈΠ΄Π΅ΠΌΠΈΡΠΌΠΈ
The present study was designed to determine the possibility of the application the genotyping of the patients with dislipidaemia as an additional factor for the prediction of the cardiovascular complications. The distribution of the polymorphism C677T of the gene MTHFR among the 62 patients with dislipidaemia was studied. Allele-specific PCR was applied for detection the C677T mutation/ These results provide the genetic evidence that 677T allele of the gene MTHFR correlates with the development of the complications of the coronary heart disease for the patients with dislipidaemia (p = 0,01). It was demonstrated that more complex and durable antihypertension and cardiotropic therapy must be applicated for the carries of the 677T allele among the dislipidaemia patients. These data indicate the appreciable role C677T polymorphism of MTHFR for the decreasing of the cardiovascular complications among the patients with dislipidaemia and for detection the complexity and longevity of the medical treatments.Π Π°Π±ΠΎΡΠ° ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»Π°ΡΡ Ρ ΡΠ΅Π»ΡΡ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π‘677Π’ Π³Π΅Π½Π° ΠΌΠ΅ΡΠΈΠ»Π΅Π½ΡΠ΅ΡΡΠ°Π³ΠΈΠ΄ΡΠΎΡΠΎΠ»Π°ΡΡΠ΅Π΄ΡΠΊΡΠ°Π·Ρ (MTHFR) Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΠΠ‘ ΠΈ Π³ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π΄ΠΈΡΠ»ΠΈΠΏΠΈΠ΄Π΅ΠΌΠΈΡΠΌΠΈ. ΠΠ»Ρ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΈ Π‘677Π’ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ Π°Π»Π»Π΅Π»Ρ-ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΠ¦Π . ΠΡΠ»Π° Π²ΡΡΠ²Π»Π΅Π½Π° ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½Π°Ρ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ ΠΌΠ΅ΠΆΠ΄Ρ Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²ΠΎΠΌ ΠΌΡΡΠ°Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π»Π»Π΅Π»Ρ 677Π’ ΠΈ ΡΠ°ΡΡΠΎΠΉ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΠΠ‘ Π² ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ
(Ρ = 0,01). ΠΠ»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π΄ΠΈΡΠ»ΠΈΠΏΠΈΠ΄Π΅ΠΌΠΈΡΠΌΠΈ Π½Π΅ Π²ΡΡΠ²Π»Π΅Π½ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎΠΉ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ ΠΌΠ΅ΠΆΠ΄Ρ Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²ΠΎΠΌ ΠΌΡΡΠ°Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π»Π»Π΅Π»Ρ 677Π’ Π³Π΅Π½Π° MTHFR ΠΈ ΡΠ°ΡΡΠΎΡΠΎΠΉ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ ΠΈ ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΡΡΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π³ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ (Ρ = 0,8). ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΠΌΠ΅ΡΡ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π΄Π»Ρ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΠΈΡΠΊΠ° ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½Π½ΠΎΠ³ΠΎ ΠΈ Π½Π΅ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π΄ΠΈΡΠ»ΠΈΠΏΠΈΠ΄Π΅ΠΌΠΈΡΠΌΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ Π΄Π»Ρ Π²ΡΠ±ΠΎΡΠ° ΠΎΠ±ΡΠ΅ΠΌΠ° ΠΈ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠΌΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π³ΠΈΠΏΠΎΠ»ΠΈΠΏΠΈΠ΄Π΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ΅Π΄ΡΡΠ²
ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΎΡΡΡΠΎΠΉ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ (ΠΠΠ) ΠΏΡΠΈ ΠΎΡΠ΅Π½ΠΊΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π³Π΅Π½Π° ITGB3
ITGB3 polymorphism affects some particular features of acute coronary insufficiency (ACI) and initially determines different patientsβ condition according to the genotype of comorbidity, characteristics of atherosclerotic process in the coronary arteries, speed of the development of ACI, patientβs response to stress, platelet-vascular hemostasis mechanism, tolerance to drug therapy.ΠΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌ Π³Π΅Π½Π° ITGB3 ΠΎΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΎΡΡΡΠΎΠΉ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ, ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡ ΠΈΡΡ
ΠΎΠ΄Π½ΠΎ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΉ ΡΡΠ°ΡΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° ΠΏΠΎ ΡΠΎΠΏΡΡΡΡΠ²ΡΡΡΠΈΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌ, ΠΏΠΎ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΡ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° Π² ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΡ
Π°ΡΡΠ΅ΡΠΈΡΡ
, ΠΏΠΎ ΡΠΊΠΎΡΠΎΡΡΠΈ ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΎΡΡΡΠΎΠΉ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ, ΡΠ΅Π°ΠΊΡΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π½Π° ΡΡΡΠ΅ΡΡ, ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠ°ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠ³ΠΎ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠ° Π³Π΅ΠΌΠΎΡΡΠ°Π·Π°, ΡΠΎΠ»Π΅ΡΠ°Π½ΡΠ½ΠΎΡΡΡ ΠΊ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
Activity of fin-systems of artificial cointegrative pAP42/pRSF2124 and pAP42/pUB781 plasmids
The fin-systems finV and finU in cointegrative plasmids are shown to produce a much stronger transfer-inhibitory effect as compared to the sum of effects produced by FinU (in transfer factor pAP42) and FinV (in nonconjugative plasmids pRSF2124 and pUB781) separately. Β© 1995 Plenum Publishing Corporation
Activity of fin-systems of artificial cointegrative pAP42/pRSF2124 and pAP42/pUB781 plasmids
The fin-systems finV and finU in cointegrative plasmids are shown to produce a much stronger transfer-inhibitory effect as compared to the sum of effects produced by FinU (in transfer factor pAP42) and FinV (in nonconjugative plasmids pRSF2124 and pUB781) separately. Β© 1995 Plenum Publishing Corporation
ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΠΏΡΡ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π³Π΅Π½Π° SEPS1 ΠΏΡΠΈ ΠΌΡΠΆΡΠΊΠΎΠΌ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΠΈ
Diagnosing male infertility is very important, as the frequency of pathospermia has reached 40-50% among infertile married couples. The article provides an example of the clinical molecular genetic diagnosis of male infertility. We investigated SEPS1polymorphism as a marker of inflammation in the idiopathic form of pathospermia. Our survey results show that a patient with asthenozoospermia is the carrier of the A allele (heterozygous type AG). The study of the polymorphism of SEPS1 G-105A as a new genetic marker of male infertility is important in modern urology.ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΌΡΠΆΡΠΊΠΎΠ³ΠΎ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΡ Π²Π°ΠΆΠ½Π°, ΡΠ°ΠΊ ΠΊΠ°ΠΊ ΡΠ°ΡΡΠΎΡΠ° ΠΏΠ°ΡΠΎΡΠΏΠ΅ΡΠΌΠΈΠΈ Π² ΡΡΡΡΠΊΡΡΡΠ΅ Π±Π΅ΡΠΏΠ»ΠΎΠ΄Π½ΠΎΠ³ΠΎ Π±ΡΠ°ΠΊΠ° Π΄ΠΎΡΡΠΈΠ³Π»Π° 40-50%. Π ΡΡΠΎΠΉ ΡΡΠ°ΡΡΠ΅ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΡΠΈΠΌΠ΅Ρ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΌΡΠΆΡΠΊΠΎΠ³ΠΎ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΡ. ΠΡ Π²ΠΈΠ·ΡΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π»ΠΈ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌ Π³Π΅Π½Π° SEPS1, ΠΊΠ°ΠΊ ΠΌΠ°ΡΠΊΠ΅Ρ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ, ΠΏΡΠΈ ΠΈΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠΌΠ΅ ΠΏΠ°ΡΠΎΡΠΏΠ΅ΡΠΌΠΈΠΈ. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π½Π°ΠΌΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΡΡ, ΡΡΠΎ ΠΏΠ°ΡΠΈΠ΅Π½Ρ Ρ Π°ΡΡΠ΅Π½ΠΎΠ·ΠΎΠΎΡΠΏΠ΅ΡΠΌΠΈΠ΅ΠΉ ΡΠ²Π»ΡΠ΅ΡΡΡ Π½ΠΎΡΠΈΡΠ΅Π»Π΅ΠΌ Π°Π»Π»Π΅Π»Ρ Π (Π³Π΅ΡΠ΅ΡΠΎΠ·ΠΈΠ³ΠΎΡΠ½ΡΠΉ ΡΠΈΠΏ AG). ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π³Π΅Π½Π° SEPS1 G-105A, ΠΊΠ°ΠΊ Π½ΠΎΠ²ΠΎΠ³ΠΎ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΌΠ°ΡΠΊΠ΅ΡΠ° ΠΌΡΠΆΡΠΊΠΎΠ³ΠΎ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΡ, Π°ΠΊΡΡΠ°Π»ΡΠ½ΠΎ Π² ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ
Genetic regulation systems of cointegrative plasmid transfer in E. coli K-12 cells
[No abstract available
ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΠΏΡΡ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π³Π΅Π½Π° SEPS1 ΠΏΡΠΈ ΠΌΡΠΆΡΠΊΠΎΠΌ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΠΈ
Diagnosing male infertility is very important, as the frequency of pathospermia has reached 40-50% among infertile married couples. The article provides an example of the clinical molecular genetic diagnosis of male infertility. We investigated SEPS1polymorphism as a marker of inflammation in the idiopathic form of pathospermia. Our survey results show that a patient with asthenozoospermia is the carrier of the A allele (heterozygous type AG). The study of the polymorphism of SEPS1 G-105A as a new genetic marker of male infertility is important in modern urology.ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΌΡΠΆΡΠΊΠΎΠ³ΠΎ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΡ Π²Π°ΠΆΠ½Π°, ΡΠ°ΠΊ ΠΊΠ°ΠΊ ΡΠ°ΡΡΠΎΡΠ° ΠΏΠ°ΡΠΎΡΠΏΠ΅ΡΠΌΠΈΠΈ Π² ΡΡΡΡΠΊΡΡΡΠ΅ Π±Π΅ΡΠΏΠ»ΠΎΠ΄Π½ΠΎΠ³ΠΎ Π±ΡΠ°ΠΊΠ° Π΄ΠΎΡΡΠΈΠ³Π»Π° 40-50%. Π ΡΡΠΎΠΉ ΡΡΠ°ΡΡΠ΅ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΡΠΈΠΌΠ΅Ρ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΌΡΠΆΡΠΊΠΎΠ³ΠΎ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΡ. ΠΡ Π²ΠΈΠ·ΡΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π»ΠΈ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌ Π³Π΅Π½Π° SEPS1, ΠΊΠ°ΠΊ ΠΌΠ°ΡΠΊΠ΅Ρ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ, ΠΏΡΠΈ ΠΈΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠΌΠ΅ ΠΏΠ°ΡΠΎΡΠΏΠ΅ΡΠΌΠΈΠΈ. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π½Π°ΠΌΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΡΡ, ΡΡΠΎ ΠΏΠ°ΡΠΈΠ΅Π½Ρ Ρ Π°ΡΡΠ΅Π½ΠΎΠ·ΠΎΠΎΡΠΏΠ΅ΡΠΌΠΈΠ΅ΠΉ ΡΠ²Π»ΡΠ΅ΡΡΡ Π½ΠΎΡΠΈΡΠ΅Π»Π΅ΠΌ Π°Π»Π»Π΅Π»Ρ Π (Π³Π΅ΡΠ΅ΡΠΎΠ·ΠΈΠ³ΠΎΡΠ½ΡΠΉ ΡΠΈΠΏ AG). ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π³Π΅Π½Π° SEPS1 G-105A, ΠΊΠ°ΠΊ Π½ΠΎΠ²ΠΎΠ³ΠΎ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΌΠ°ΡΠΊΠ΅ΡΠ° ΠΌΡΠΆΡΠΊΠΎΠ³ΠΎ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΡ, Π°ΠΊΡΡΠ°Π»ΡΠ½ΠΎ Π² ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ
POLYMORPHISMS OF GSTP1 GENE AND PATHOSPERMIA AS A MALE INFERTILITY FACTORS IN MOSCOW
Infertility affects 15% of married couples and 45-50% of cases are caused by impaired spermatogenesis. It is known that free reactive oxygen species (ROS) reduce sperm motility. Glutathione-S-transferase (GSTP1) is an important multifunctional ejaculate protein, providing protection against xenobiotic and ROS. The purpose of the research is to study the association of Ile105Val and Ala114Val polymorphisms of the GSTP1 gene with risk of pathospermia as a male infertility factor in Moscow region. Our study reveals that the 105Val (G) and 114Val (T) alleles of GSTP1 gene are the genetic risk factors for unexplained male infertility, especially in the patients with teratospermia
ΠΠ΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΠ²Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΎΠ»ΠΈ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° <i>G-105A </i>Π³Π΅Π½Π° <i>SEPS1 </i>ΠΏΡΠΈ ΠΌΡΠΆΡΠΊΠΎΠΌ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΠΈ
About 30 million men in the world are infertile. Genetic factors are the cause of 15-30% of cases of pathospermia. Purpose. To study the influence of polymorphism G-105A (rs28665122) of SEPS1 gene on the development of pathospermia among men with infertility in Moscow region. Patients and methods. There were examined 138 men. All patients were divided on 2 groups: the first (n = 70) - patients with pathospermia, the second (control) - fertile men (n = 68). All patients underwent clinical examination: analysis of spermograms, determination of hormonal profile, ultrasound of scrotum organs. We performed a genetic analysis of peripheral blood leukocyte DNA in patients of both groups. All DNA samples were studied for the presence of polymorphism G-105A (rs28665122) SEPS1 gene using polymerase chain reaction methods and the analysis of restriction fragments length polymorphism (PCR-RFLP). Results. All patients of the first group suffered from severe infertility. Of these, 26 (37.14%) men had asthenozoospermia, 23 (32.85%) men with teratozoospermia, 21 (30.0%) - azoospermia. A clinical study of patients of the first group did not reveal any serious deviations from the norm, so we were installed they idiopathic infertility. Our study of gene polymorphism SEPS1 showed that patients with pathospermia have allele -105Π (genotypes GA+AA) a twice as often as in the control group of fertile men (48.57% ΠΈ 27.94%, respectively, p < 0.001). Conclusion. Polymorphism G -105A SEPS1 gene may be used for screening of infertility in men.ΠΠΎΡΡΠΈ 30 ΠΌΠ»Π½ ΠΌΡΠΆΡΠΈΠ½ Π²ΠΎ Π²ΡΠ΅ΠΌ ΠΌΠΈΡΠ΅ ΡΠ²Π»ΡΡΡΡΡ Π±Π΅ΡΠΏΠ»ΠΎΠ΄Π½ΡΠΌΠΈ. ΠΠΎΡΡΠ΄ΠΊΠ° 15-30% ΡΠ»ΡΡΠ°Π΅Π² ΡΡΠΆΠ΅Π»ΡΡ
ΡΠΎΡΠΌ ΠΏΠ°ΡΠΎΡΠΏΠ΅ΡΠΌΠΈΠΈ Ρ ΠΌΡΠΆΡΠΈΠ½ ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½Ρ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ. Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΠ·ΡΡΠΈΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° G-105A (rs28665122) Π³Π΅Π½Π° SEPS1 Π½Π° ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΏΠ°ΡΠΎΡΠΏΠ΅ΡΠΌΠΈΠΈ ΡΡΠ΅Π΄ΠΈ ΠΌΡΠΆΡΠΈΠ½ Ρ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΠ΅ΠΌ ΠΠΎΡΠΊΠΎΠ²ΡΠΊΠΎΠ³ΠΎ ΡΠ΅Π³ΠΈΠΎΠ½Π°. ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠ»ΠΎ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΎ 138 ΠΌΡΠΆΡΠΈΠ½. ΠΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Π±ΡΠ»ΠΈ ΠΏΠΎΠ΄Π΅Π»Π΅Π½Ρ Π½Π° 2 Π³ΡΡΠΏΠΏΡ: ΠΏΠ΅ΡΠ²Π°Ρ ( n = 70) - ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ ΠΏΠ°ΡΠΎΡΠΏΠ΅ΡΠΌΠΈΠ΅ΠΉ, Π²ΡΠΎΡΠ°Ρ (ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ) - ΡΠ΅ΡΡΠΈΠ»ΡΠ½ΡΠ΅ ΠΌΡΠΆΡΠΈΠ½Ρ ( n = 68). ΠΡΠ΅ΠΌ Π±ΠΎΠ»ΡΠ½ΡΠΌ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅: Π°Π½Π°Π»ΠΈΠ· ΡΠΏΠ΅ΡΠΌΠΎΠ³ΡΠ°ΠΌΠΌΡ, ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π³ΠΎΡΠΌΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ, Π£ΠΠ ΠΎΡΠ³Π°Π½ΠΎΠ² ΠΌΠΎΡΠΎΠ½ΠΊΠΈ. ΠΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΠΠ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠΎΠ² ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΎΠ±Π΅ΠΈΡ
Π³ΡΡΠΏΠΏ. ΠΡΠ΅ ΠΎΠ±ΡΠ°Π·ΡΡ ΠΠΠ ΠΈΠ·ΡΡΠ°Π»ΠΈ Π½Π° ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° G-105A (rs28665122) Π³Π΅Π½Π° SEPS1 Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ Ρ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠΈΠΌ Π°Π½Π°Π»ΠΈΠ·ΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π΄Π»ΠΈΠ½ ΡΠ΅ΡΡΡΠΈΠΊΡΠΈΠΎΠ½Π½ΡΡ
ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΎΠ². Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ 1-ΠΉ Π³ΡΡΠΏΠΏΡ ΡΡΡΠ°Π΄Π°Π»ΠΈ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΡ. ΠΠ· Π½ΠΈΡ
Ρ 26 (37,14%) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π±ΡΠ»Π° Π·Π°ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½Π° Π°ΡΡΠ΅Π½ΠΎΠ·ΠΎΠΎΡΠΏΠ΅ΡΠΌΠΈΡ, Ρ 23 (32,85%) ΠΌΡΠΆΡΠΈΠ½ - ΡΠ΅ΡΠ°ΡΠΎΠ·ΠΎΠΎΡΠΏΠ΅ΡΠΌΠΈΡ, Ρ 21 (30,0%) - Π°Π·ΠΎΠΎΡΠΏΠ΅ΡΠΌΠΈΡ. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² 1-ΠΉ Π³ΡΡΠΏΠΏΡ Π½Π΅ Π²ΡΡΠ²ΠΈΠ»ΠΈ ΠΊΠ°ΠΊΠΈΡ
-Π»ΠΈΠ±ΠΎ Π³ΡΡΠ±ΡΡ
ΠΎΡΠΊΠ»ΠΎΠ½Π΅Π½ΠΈΠΉ ΠΎΡ Π½ΠΎΡΠΌΡ, ΠΏΠΎΡΡΠΎΠΌΡ Π±ΡΠ»ΠΎ Π·Π°ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½ΠΎ ΠΈΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΠ΅. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π³Π΅Π½Π° SEPS1 ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ, ΡΡΠΎ ΡΡΠ΅Π΄ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΠ°ΡΠΎΡΠΏΠ΅ΡΠΌΠΈΠ΅ΠΉ Π½ΠΎΡΠΈΡΠ΅Π»ΠΈ Π°Π»Π»Π΅Π»Ρ -105Π (Π³Π΅Π½ΠΎΡΠΈΠΏΡ GA+AA) Π²ΡΡΡΠ΅ΡΠ°ΡΡΡΡ ΠΏΠΎΡΡΠΈ Π² 2 ΡΠ°Π·Π° ΡΠ°ΡΠ΅, ΡΠ΅ΠΌ Π² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ ΡΠ΅ΡΡΠΈΠ»ΡΠ½ΡΡ
ΠΌΡΠΆΡΠΈΠ½ (48,57% ΠΈ 27,94% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ, p < 0,001). ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌ G-105A Π³Π΅Π½Π° SEPS1 ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ Π΄Π»Ρ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π° Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΡ Ρ ΠΌΡΠΆΡΠΈΠ½
- β¦